Table 2 |
||||||||||
|
Study Flowchart |
||||||||||
|
Visit |
Admission |
Day 2 |
Day 5 |
Day 10 |
Day 14 |
Day 21 |
Day 28 |
Day 35 |
Discharge |
3 months |
|
|
||||||||||
|
Informed consent |
X |
|||||||||
|
Clinical scores |
X |
X |
X |
X |
X |
X |
X |
X |
X |
|
|
US# |
X |
X |
||||||||
|
CT* |
X |
|||||||||
|
Laboratory |
X |
X |
X |
X |
X |
X |
X |
X |
||
|
Study product |
X§ |
X§ |
X |
X |
X |
X |
X |
|||
|
|
||||||||||
|
# US = abdominal ultrasound to detect gallstones (at admission) or pseudocyste (at follow-up) * CT = abdominal computer tomographic scan to detect (peri-)pancreatic necrosis § = Within 72 hours after onset of pain the administration of the study product is started. |
||||||||||
|
Besselink et al. BMC Surgery 2004 4:12 doi:10.1186/1471-2482-4-12 |
||||||||||
